RedCare Pharmacy (RDCP), currently trading at $132.76, reported a robust financial performance for the fourth quarter of 2024, highlighted by significant sales growth and strategic market expansions.

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...